BARD1 INVESTOR PRESENTATION

Melbourne, Australia, 7 July 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) is pleased to release an Investor Presentation that will be used to update shareholders, brokers and investors on the Company, its pipeline and commercialisation plans.

The presentation will be delivered by CEO Dr Leearne Hinch and is attached to this announcement.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

Dr Geoff Cumming
Non-Executive Chairman
E geoff.cumming@bard1.com
M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. BARD1 has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.

BARDI
LIFE SCIENCES LIMITED

Detecting cancer earlier to save lives

Investor Presentation | July 2021



Important notice and disclaimer

The following notice and disclaimer applies to this investor presentation (Presentation or document) and you are therefore advised to read this carefully before reading or making any other use of this Presentation or any information contained in this Presentation. By accepting this Presentation you represent and warrant that you are entitled to receive the Presentation in accordance with the terms, and agree to be bound by the limitations, contained within it.

This Presentation is being delivered on behalf of BARD1 to you and the information contained in it is strictly confidential and is intended exclusively for you until it is either publicly released or BARD1 or its advisers inform you otherwise. By accepting this Presentation, you agree that this Presentation shall not be copied or reproduced in any manner whatsoever or distributed to others, whether in whole or in part, at any time without the prior written consent of BARD1 which may be withheld in its absolute discretion, unless this Presentation is publicly released. You also agree that you will use this Presentation only for the purpose of the appraisal of the investment opportunity. You further agree that on request by BARD1 that you will promptly return or permanently destroy or delete any copy of this Presentation.

Summary information
This Presentation is dated 7 July 2021 and provides information in summary form and general information regarding BARD1 Life Sciences Limited ACN 009 070 384 (BARD1 or the Company).

This presentation should be read in conjunction with the Company's other periodic and continuous disclosure information lodged with the ASX, which are available at www.asx.com.au. Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. None of the Company, its representatives or advisers have independently verified any such market or industry data provided by third parties or industry or general publications.

Statements made in this Presentation are made only as at the date of this Presentation and are made for information purposes only. The information in this Presentation remains subject to change without notice.

Not an offer
This Presentation is for information purposes only and is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or any other law (and will not be lodged with the Australian Securities and Investments Commission (ASIC)). This Presentation is not complete, is intended only as an outline and has been prepared by and issued by BARD1 to assist in informing interested parties about the Company and should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in the Company will be entered into on the basis of this Presentation and this Presentation does not and will not form any part of any contract for the acquisition of securities.

This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. This presentation is not for release to US wire services or distribution in the United States or any country where it may be unlawful.

Not financial product advice
This Presentation does not constitute financial product or investment advice or any recommendation to acquire shares in BARD1 or accounting, legal or tax advice. It has been prepared without taking into account the objectives, financial or tax situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and obtain legal and taxation advice appropriate to their jurisdiction and particular circumstances. BARD1 is not licensed to provide financial product advice or any other financial products.

Investment risk
An investment in the Company's shares is subject to investment and other known and unknown risks, some of which are beyond the control of BARD1 including loss of income and principal invested. BARD1 does not guarantee any particular rate of return or performance or any particular tax treatment. Prospective investors should have regard to the risks set out in the Company's 2020 Annual Report released to the ASX on 25 August 2020 before investing in the Company.

If you have any queries or concerns about investing in New Shares you should seek independent financial, legal or accounting advice.

Financial and other data
All dollar values are in Australian dollars (A$ or AUD) unless otherwise stated. A number of figures, amounts, percentages, estimates and calculations of value in this Presentation are approximations or are subject to the effect of rounding.

Prospective investors should also be aware that any pro-forma financial information included in this Presentation is for illustrative purposes and does not purport to be in compliance with Article 11 of Regulation S-X of the rules and regulations of the United States Securities and Exchange Commission. Prospective investors should be aware that certain financial data that may be included in this presentation is "non-IFRS financial information" under ASIC Regulatory Guide 230 Disclosing non-IFRS financial information published by ASIC and also "non-GAAP financial measures" within the meaning of Regulation G under the U.S. Securities Exchange Act of 1934. Non-IFRS/non-GAAP measures include the pro-forma financial information.

While the Company believes that this non-IFRS/non-GAAP financial information provides useful information to users in measuring the financial position and conditions of the Company, the non-IFRS/non-GAAP financial information does not have a standardised meaning prescribed by Australian Accounting Standards and, therefore, may not be comparable to similarly titled measures presented by other entities, nor should it be construed as an alternative to other financial measures determined in accordance with Australian Accounting Standards. Prospective investors are cautioned, therefore, not to place undue reliance on any non-IFRS/non-GAAP financial information and ratios included in this Presentation.

Past and future performance
This Presentation contains certain "forward-looking statements" that are based on management's beliefs, assumptions and expectations and on information currently available to management. The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Any indications of, and guidance on, future operating performance, earnings, financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions.

Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including BARD1 or any of its advisers). In particular, no representation, warranty or assurance (express or implied) is given that the occurrence of the events expressed or implied in any forward-looking statements in this Presentation will actually occur. Actual operations, results, performance, targets or achievement may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based.

Nothing contained in this Presentation constitutes investment, legal, tax or other advice. This Presentation does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

You should note that any past performance is given for illustrative purposes only and should not be relied on as (and is not) an indication of the Company's views on its future financial performance or condition. Past performance, including past share price performance, of BARD1 cannot be relied on as an indicator of (and provides no guidance as to) future performance including future share price performance.

Disclaimer
The information in this Presentation has been obtained from or based on sources believed by BARD1 to be reliable. To the maximum extent permitted by law, the Company, its representatives and advisers, and their respective affiliates, officers, employees, agents and advisers do not make any warranty, express or implied, as to the currency, accuracy, reliability or completeness of the information in this Presentation and disclaim all responsibility and liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of the information in this Presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise.

None of the Company's representatives, advisers, nor any of their affiliates, related bodies corporate, directors, officers, employees, agents or advisers have authorised, caused or permitted the issue, submission or despatch of this Presentation nor do they make any recommendation as to whether a potential investor should acquire shares. None of them makes or purports to make any statement in this Presentation and there is no statement in this Presentation which is based on any statement by them.

Representations, warranties and acknowledgements
This Presentation is being provided to you on the basis that you are, and you represent and warrant that:

- if you are in Australia, you are the holder (or representative of a holder) of an Australian financial services licence or are a "professional investor" or "sophisticated investor" (as those terms are used in section 708(11) and section 708(8) respectively of the Corporations Act) and are also, in each case, a "wholesale client" (as defined in section 761G of the Corporations Act); or
- if you are outside Australia, you are a person to whom the provision of the information in this Presentation is permitted by laws of the jurisdiction in which you are situated without the need for registration, lodgement or approval of a formal disclosure document or any other filing or formality in accordance with the laws of that foreign jurisdiction; and
- you are not in the United States and you are not a U.S. Person (as defined in Rule 902(k) of Regulation S under the U.S. Securities Act of 1933 (U.S. Securities Act) as amended) (U.S. Person) and you are not acting for the account or benefit of any U.S. Person.

If you are not a person described above, you are not entitled to read or have access to this Presentation and must notify BARD1 immediately and promptly return this Presentation to BARD1 without retaining any copies.

International selling restrictions
This Presentation does not constitute an offer of shares in BARD1 in any jurisdiction. In particular, this Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States. The shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States. The distribution of this Presentation may be restricted by law in any country outside Australia and New Zealand. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. See further International Offer Restrictions in this Presentation. By accepting this Presentation you represent and warrant that you are entitled to receive the Presentation in accordance with these restrictions and agree to be bound by their limitations.

Executive summary

Cancer diagnostics company	• Focused on early cancer detection to save lives
Game changing technology	• Patented technologies with clear advantages for multiple cancer applications
Compelling results	• >95% sensitivity & 100% specificity for detection of breast and ovarian cancers[1]
Strong pipeline	• Pipeline for unmet needs in common and deadly cancers
Commercialised products	• Products for bladder cancer[2] and exosome research
Significant growth potential	• Targeting unmet needs in US$11b global markets
Experienced leadership	• Track record in healthcare leadership, Dx development and commercialisation

Dx = Diagnostics; 1 SubB2M proof-of-concept data; 2 Adjunct to urine cytology to assist the detection of bladder cancer

Company overview

BARD1 Life Sciences (ASX: BD1)

- Diagnostics company focused on early cancer detection
- Game-changing technology with multiple applications
- Dx pipeline for breast, ovarian, prostate & pancreatic cancers targeting US$11b global markets
- Lead products >95% se & 100% sp for all stages of breast & ovarian cancer
- GTM in partnership with clinical laboratories and diagnostics distributors
- Commercialised products for bladder cancer & exosome research

Board and management


Dr Geoff Cumming
Chairman


Max Johnston
Non-Exec Director


Phillip Powell
Non-Exec Director


Prof Allan Cripps
Non-Exec Director


Dr Leearne Hinch
Chief Executive Officer


Dr Peter French
Chief Scientific Officer


Tony Di Pietro
Company Sec / CFO


Dr Wayne Jensen
R&D Director


Dr Emily Stein
R&D Manager (USA)

BARD1 History

2016	BARD1 AAb technology acquired
2020	SubB2M and EXO-NET® technologies acquired / in-licensed
2021	SubB2M proof-of-concept results for breast and ovarian cancers
	RUO EXO-NET exosome capture tool launched

Financial information (6/7/21)	
Ordinary shares	80,056,715
Share price	A$1.85
Market capitalisation	A$148.1m
Cash position (31/3/21)	A$6.0m
Quarterly cash burn (31/3/21)	A$1.5m

Share price performance (Past 12 months)



Dx = Diagnostics; GTM = Go to market; se = sensitivity; sp = specificity

Unmet need for early cancer detection

The problem

- Screening tests often have high false-positives &/or insufficient sensitivity for early-stage cancer (I/II)
- Cancer often detected at late-stage (III/IV) after symptoms have appeared resulting in poor prognosis
- Poor screening participation due to tests being invasive, inconvenient, ineligible, inaccessible or expensive

Unmet need

- Unmet need for non-invasive, accurate and reliable screening tests for earlier detection of cancer
- Earlier detection improves treatment options, patient outcomes & 5-year survival[1]
- BARD1 is focused on earlier cancer detection to save lives

5-year survival rates by stage at diagnosis[1]



1 SEER 18 2010-2016

Diagnostics continuum

Before diagnosis

After diagnosis

Genetic tests to predict the risk of developing a cancer (e.g. BRCA1 test)

Imaging and blood tests for early detection of cancer in asymptomatic people (e.g. Screening mammography; PSA test)

Imaging and biopsy tests for confirmatory & definitive diagnosis of cancer (e.g. OVA1)

Genomic, tissue and blood tests for staging and treatment selection to match patients with the right therapy (e.g. BRACAnalysis CDx®)

Imaging and blood tests to monitor treatment response and recurrence in patients diagnosed with cancer (e.g. CA125 test)

CDx = Companion diagnostics; BRACAnalysis CDx is a registered trademark of Myriad Genetics

Products and pipeline

- Marketed products for bladder cancer[1] & exosome research
- Lead pipeline products for breast & ovarian cancer
- Focused on cancer screening & monitoring



PRODUCT	INDICATION	PLATFORM	USE	RESEARCH	ASSAY DEVELOPMENT	CLINICAL VALIDATION	MARKETING AUTHORISATION	NEXT MILESTONE
hTERT	Bladder Cancer	ICC (Urine)	Adjunct to cytology	→	→	→	In-market	China registration
EXO-NET-RUO	Exosome Capture	Molecular NET (Biofluid)	Research tool	→	→	→	In-market	First revenues
SubB2M-BCM	Breast Cancer	ELISA (Serum)	Monitoring	→	→	**LEAD PIPELINE PRODUCTS**	2023	Feasibility results
SubB2M-OCM	Ovarian Cancer	ELISA (Serum)	Monitoring	→	→		2023	Feasibility results
SubB2M-PCS	Prostate Cancer	ELISA (Serum)	Screening	→			**	Feasibility results
SubB2M-PaCS	Pancreatic Cancer	ELISA (Serum)	Screening	→			**	
BARD1-Ovarian	Ovarian Cancer	ELISA (Serum)	Screening	→			**	
BARD1-Breast[2]	Breast Cancer	ELISA (Serum)	Screening	→				
BARD1-Lung[2]	Lung Cancer	ELISA (Serum)	Screening	→				

*RUO = Research Use Only; ELISA = Enzyme Linked Immunosorbent Assay; **Dates will be released when projects are further advanced
1 Adjunct to urine cytology to assist the detection of bladder cancer; 2 Progression subject to outcome of BARD1-Ovarian results

Global cancer diagnostics market

- Global cancer burden: 50.6m people[1]
- 19.3m new cases and 10.0m deaths p.a.[1]
- Global cancer diagnostics market worth US$250b[2]
- BARD1 is targeting markets valued at US$11b for some of the world's most common and deadliest cancers

#	Cancer[1]	Prevalence	Incidence	Deaths
1	**Breast**	7,790,717	2,261,419	684,996
3	**Prostate**	4,956,901	1,414,259	375,304
17	**Ovarian**	823,315	313,959	207,252
22	**Pancreatic**	379,958	495,773	466,003



1 GLOBOCAN (IARC) 2020; 2 Grand View Research 2019. https://www.grandviewresearch.com/press-release/global-cancer-diagnostics-market; 3 https://www.grandviewresearch.com/industry-analysis/breast-cancer-diagnostics-market; 4 https://www.grandviewresearch.com/industry-analysis/ovarian-cancer-diagnostics-market; 5 https://www.grandviewresearch.com/industry-analysis/prostate-cancer-diagnostics-market; 6 https://www.wboc.com/story/43615802/pancreatic-cancer-diagnostic-market-size-2021-with-a-cagr-of-69-top-companies-data-report-covers-market-specific-challenges-brief-analysis-and

SubB2M™ | technology

Game-changing technology for early detection and monitoring of cancer

- SubB2M is an engineered protein that specifically binds to a unique sugar Neu5Gc
- Neu5Gc is a pan-cancer marker found in human cancer tissues, cells and secretions[1]
- BARD1 has the exclusive worldwide licence to SubB2M technology for diagnostic applications[2]
- Strong patent position covering composition of matter and method claims for SubB2M and detection of Neu5Gc expressed by tumour cells
- Multiple applications for early cancer detection and monitoring
- Focused on developing and commercialising SubB2M-based blood tests for breast and ovarian cancers

- ✓ POC results in breast and ovarian cancers show over 95% sensitivity and 100% specificity across all cancer stages[3]
- ✓ Small-scale SubB2M supply agreement with University of Adelaide
- ✓ Contract manufacturing agreement for GMP-grade SubB2M being negotiated
- ✓ Collaborative research agreements in place with Institute for Glycomics at Griffith University to develop SubB2M-based blood tests for breast and ovarian cancers
- ✓ Initiated discussions with potential laboratory partners for commercialisation of SubB2M-based blood tests

1 Neu5Gc is not expressed in normal human tissue; 2 License from University of Adelaide and Griffith University; 3 Shewell et al. *N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease*". 2021: https://biorxiv.org/cgi/content/short/2021.06.21.449179v1

SubB2M™| breast cancer test

POC results show >95% sensitivity and 100% specificity for all BC stages

Test	• SubB2M-based ELISA for early detection and monitoring of BC
Results	• POC study using SPR-based assay to evaluate detection of Neu5Gc in BC showed >95% sensitivity and 100% specificity across all stages (I - IV) compared to healthy controls[3,4]
Next steps	• Feasibility studies to transfer & evaluate ELISA-based test compared to SPR (commenced)[5] • Assay development & clinical testing for detection of BC compared to CA15.3 • Technical & clinical validation studies by laboratory partner
Additional research	• Expand indications to screening high-risk, asymptomatic women compared to mammography • Expand indications to screening average-risk, asymptomatic women

Stage	Breast Cancer (96 cancers : 22 controls)		
	Sensitivity	Specificity	AUC
Stage I	95.83%	100%	0.958
Stage II	100%	100%	1.000
Stage III	100%	100%	1.000
Stage IV	100%	100%	1.000

POC = Proof of Concept; SPR = Surface Plasmon Resonance; BC = Breast Cancer; AUC = Receiver Operating Characteristic Area Under the Curve;
1 SEER 18 2011-2017 https://seer.cancer.gov/statfacts/html/breast.html; 2 Cancer Today 2020 data; 3 Pre-print manuscript available https://biorxiv.org/cgi/content/short/2021.06.21.449179v1;
4 Samples provided by Victorian Cancer Biobank; 5 Awarded competitive BTB funding from MTPConnect to develop tests for monitoring & detection of BC

Market potential | US breast cancer screening

- World's most common cancer (2.3m new cases & 685k deaths pa)[1]
- US: 3.7m survivors, 234k new cases & 43k deaths pa[1,2]
- Life-time risk of 12.9% [2]
- Screening using mammography recommended for average-risk women[2]
- Issues with high false positives, safety and self-exclusion due to discomfort, inconvenience and cost
- Unmet need for a blood test to screen women who are ineligible, can't access, self-exclude or at high-risk
- Early detection can improve QOL, treatment options & survival (from 29% at late-stage to 99%)[2]

Indicative Price \ Market Penetration	US Breast Cancer Market pa (USD)		
	10%	20%	30%
$125	$0.4 bn	$0.8 bn	$1.3 bn
$250	$0.8 bn	$1.7 bn	$2.5 bn
$500	$1.7 bn	$3.3 bn	$5.0 bn

Key Assumptions (US market):

- Target population: 66.8m women aged 45 - 74 years[3,4]
- Screening frequency: biennial[4]
- Price: indicative pricing only[5]

QOL = Quality of Life; 1 Cancer Today 2020 data; 2 SEER 18 2011-2017 https://seer.cancer.gov/statfacts/html/breast.html; 3 US Census. International Data Base (IDB). 2021. https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2021&FIPS_SINGLE=US&dashPages=BYAGE&ageGroup=5Y; 4 ACS 2021 https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html; 5 This is not a sales forecast.

SubB2M™| ovarian cancer test

POC results show 100% sensitivity and 100% specificity for all OC stages

Test	• SubB2M-based ELISA for early detection and monitoring of OC
Results	• POC study using SPR-based assay to evaluate detection of Neu5Gc in OC showed 100% sensitivity and 100% specificity across all stages (I - IV) compared to healthy controls[3,4]
Next steps	• Feasibility studies to transfer & evaluate ELISA-based test compared to SPR (commenced)[5] • Assay development & clinical testing for detection of OC compared to CA125 • Technical & clinical validation studies by laboratory partner
Additional research	• Expand indications to screening high-risk, asymptomatic women • Expand indications to screening average-risk, asymptomatic women

Stage	Ovarian Cancer (47 cancers : 22 controls)		
	Sensitivity	Specificity	AUC
Stage I	100%	100%	0.958
Stage II	100%	100%	1.000
Stage III	100%	100%	1.000
Stage IV	100%	100%	1.000

POC = Proof of Concept; SPR = Surface Plasmon Resonance; OC = Ovarian Cancer; AUC = Receiver Operating Characteristic Area Under the Curve;
1 SEER 18 2011-2017 https://seer.cancer.gov/statfacts/html/breast.html; 2 Cancer Today 2020 data; 3 Pre-print manuscript available https://biorxiv.org/cgi/content/short/2021.06.21.449179v1;
4 Samples provided by Victorian Cancer Biobank; 5 Awarded competitive BTB funding from MTPConnect to develop tests for monitoring & detection of BC

Market potential | US ovarian cancer screening

- World's deadliest gynaecological cancer (314k new cases & 207k deaths pa)[1]
- US: 235k survivors, 24k new cases & 14k deaths pa[1,2]
- Life-time risk of 1.2%, increases to 35-70% with *BRCA1* mutation [2,4]
- Average 5-year survival 49% due to late-stage detection after symptoms have appeared (57%)[2]
- Screening with CA125 test and TVUS may be offered to high-risk women[4]
- Unmet need for an accurate & reliable screening test for OC
- Early detection can improve QOL, treatment options & survival (from 30% at late-stage to 93%)[2]

	Market Penetration	US Ovarian Cancer Market pa (USD)		
		10%	20%	30%
Indicative Price	$125	$0.6 bn	$1.3 bn	$1.9 bn
	$250	$1.3 bn	$2.5 bn	$3.8 bn
	$500	$2.5 bn	$5.1 bn	$7.6 bn

Key Assumptions (US market):

- Target population: 50.5m women aged 50 - 74 years[3]
- Screening frequency: annual
- Price: indicative pricing only[5]

QOL = Quality of Life; 1 Cancer Today 2020 data; 2 SEER 18 2011-2017 https://seer.cancer.gov/statfacts/html/ovary.html; 3 US Census. International Data Base (IDB). 2021. https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2021&FIPS_SINGLE=US&dashPages=BYAGE&ageGroup=5Y; 4 ACS 2021 https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/detection.html; 5 This is not a sales forecast.

SubB2M™ | ELISA-based test method

- Simple ELISA-based method used in high throughput commercial laboratories worldwide
- Developing pan-cancer SubB2M test (ELLBA) for monitoring cancer treatment response or recurrence
- Developing cancer-specific SubB2M tests (ELISA) for early detection of cancers based on Neu5Gc carrying tissue-specific biomarkers
- Potential to improve the specificity of existing commercial cancer tests and develop fast-to-market, next generation products for detection of ovarian (CA125), breast (CA15.3) and prostate cancers (PSA)



ELLBA = Enzyme Linked Lectin Binding Assay; ELISA = Enzyme Linked ImmunoSorbent Assay; HRP = Horseradish Peroxidase

SubB2M | goals and strategy

GOAL is to develop and commercialise superior blood tests for early cancer detection and monitoring

Develop SubB2M-based ELISA	• Complete assay development of SubB2M-based ELISA compatible with high-throughput laboratory workflow (assay development)
Advance lead Dx pipeline	• Advance clinical testing & validation of SubB2M tests for early detection & monitoring of breast and ovarian cancers • Analytical validation of reliability (range, LOD, precision, interference, etc) • Clinical validation of accuracy (Se, Sp, PPV, NPV & Accuracy)
LDT commercial-isation	• Commercialise first as LDTs with CLIA certified laboratory partner/s in the US • Fast-to-market pathway enabling early revenues, access to ‘real world’ data (acceptable to FDA), build biobank & reimbursement case, and gain market acceptance
IVD regulatory authorisation	• IVD medical device pathway dependant on use (510k/De Novo/PMA submission) • Larger-scale, multi-site clinical studies to prove safety & efficacy in intended use population • Enables deeper clinical adoption, market access and reimbursement of kit
Expand applications	• Expand uses to BC and OC screening in high-risk & average-risk asymptomatic women • Expand cancer applications to prostate, pancreatic & others • Expand technology applications to improve specificity of CTC, PET & others

ELISA = Enzyme Linked Immunosorbent Assay; LDT = Laboratory Developed Test; CLIA = Clinical Laboratory Improvement Amendment;; IVD = In Vitro Diagnostic; FDA = US Food and Drug Administration; BC = Breast Cancer; OC = Ovarian Cancer; CTC = Circulating Tumour Cell; PET = Position Emission Tomography

SubB2M | activity timeline



Milestones and timelines subject to change based on results, partner/regulatory engagement; impact of COVID-19 delays, and other factors outside of management control

Other research projects

Additional research projects are being evaluated for other cancers and indications for use

EXO-NET® technology projects

- EXO-NET is a **molecular NET technology for capture of exosomes**
- **Exosomes** are nano-particles (30-150nm) produced by cells containing nucleic acids, proteins & lipids that are **biomarkers** for diagnosis and treatment of multiple diseases including cancer
- Potential applications as **liquid biopsies** to replace tissue biopsies[1]

Product opportunities:

- **IVD EXO-NET** product for isolation of exosomes for diagnostic purposes
- Exosome-based **cancer diagnostics** using customised IVD EXO-NETs
- Novel exosome-based **companion diagnostics (CDx)**

BARD1 AAb technology projects

- BARD1 technology **detects autoantibodies to variant BARD1 proteins** associated with cancer formation, progression and poor prognosis
- Potential applications for **early cancer detection**
- **POC studies** performed at UNIGE[2] using a research-stage ELISA show high predictive accuracy for detection of ovarian, breast & lung cancers compared to healthy controls
- Further assay design, development and validation is required before advancing to clinical development[3]

PRODUCTS[1]	INDICATION	PLATFORM	USE	RESEARCH	ASSAY DEVELOPMENT	CLINICAL VALIDATION	MARKETING AUTHORISATION*
EXO-NET-001		Molecular NET (Biofluid)		→			
BARD1-Ovarian[3]	Ovarian Cancer	ELISA (Serum)	Screening	⟶			
BARD1-Breast[4]	Breast Cancer	ELISA (Serum)	Screening	⟶			
BARD1-Lung[4]	Lung Cancer	ELISA (Serum)	Screening	→			
B009	Type 3c Diabetes	ELISA (Serum)	Screening	→			

ELISA = Enzyme Linked ImmunoSorbent Assay; *Dates will be released when projects are further advanced; 1 Liquid biopsies include exosomes, CTC & CtDNA; 2 UNIGE = University of Geneva; 3 Further assay design, development and validation is required before advancing to clinical development; 4 Progression subject to outcome of BARD1-Ovarian results

Products

Two products in-market for exosome research and detection of hTERT

RUO EXO-NET® (launched May 2021)

- RUO EXO-NET is a research use only **pan-exosome capture tool**
- Suitable for **blood, urine, saliva** and **cell culture**
- Highly scalable with **speed, purity and yield** advantages
- 1ml vial enables preparation of up to 50 samples
- Available for purchase via www.exo-net.com
- Multiple evaluations underway with KOLs in academia & industry
- Embeds EXO-NET into the discovery, development & commercialisation phases of future **exosome-based Dx and Tx**
- Research market estimated at **US$100-500m** by 2026[1]

Anti-hTERT Antibody

- hTERT test is an **immunocytochemistry (ICC) assay that detects hTERT** and is used as an adjunct to urine cytology to assist bladder cancer diagnosis
- **Registered** as FDA Class I medical device (US), CE Mark (Europe), MFDS Class II (South Korea) & TGA listed (Australia)
- **Distributors appointed** in US, Europe & Asia
- **US**: Generating **revenue, reimbursable & focus on high-volume labs** to drive growth
- **ROW**: Establishing test in Key User / reference laboratories
- **Bladder cancer stats**: incidence 80,617, prevalence 269,259, **3.4m urine cytology tests pa** on new cases of haematuria in US[2,3]

RUO = Research Use Only; KOLs = Key Opinion Leaders; Dx = Diagnostics: Tx = Therapeutics
1 BARD1 estimate; 2 Cancer Today (IARC) 2020; 3 Pacific Edge Annual Report 2019

Catalysts and plans

Expected value-adding milestones over the next 12 months

Key catalysts

- **Feasibility results** for SubB2M-ELISA tests (studies commenced)
- **Clinical testing results** for SubB2M-based **breast cancer test**
- **Clinical testing results** for SubB2M-based **ovarian cancer test**
- Secure **laboratory partner**/s for commercialisation of diagnostic pipeline

Other milestones

- Appoint **distribution partner/s** for RUO EXO-NET®
- Expand co-development / **licensing opportunities** for EXO-NET®

Milestones and timelines subject to change based on results, partner/regulatory engagement; impact of COVID-19 delays, and other factors outside of management control

Contacts

BARD1 Life Sciences Ltd
23 Normanby Road
Notting Hill VIC 3168
Australia

P +61 3 9548 7586
E info@bard1.com
W www.bard1.com

Dr Leearne Hinch | CEO
E leearne@bard1.com
M +61 400414416



Appendices

Healthcare experienced board

DR GEOFF CUMMING PhD

Non-Executive Chairman

- Healthcare and biotechnology director with extensive diagnostics industry experience.
- Previously Managing Director Roche Diagnostic Systems (Oceania), MD/CEO Biosceptre International Ltd and MD/CEO of Anteo Diagnostics Ltd.
- Currently NED Anteo Diagnostics Ltd.

MAX JOHNSTON

Non-Executive Director

- Healthcare industry director and international business leader with extensive experience across medtech, pharmaceuticals, consumer healthcare and consumer goods.
- Previously President and CEO of Johnson & Johnson Pacific.
- Currently Chairman AusCann Group Holdings Ltd and NED of Medical Developments International Ltd.

PHILIP POWELL

Non-Executive Director

- Healthcare industry director and chartered accountant with extensive investment banking experience specialising in capital raisings, IPOs, mergers and acquisitions and other transactions across pharma, food and agriculture.
- Previously at OAMPS Ltd and Arthur Andersen.
- Currently NED Medical Developments International Ltd and RMA Global Ltd.

Prof ALLAN CRIPPS AO PhD

Non-Executive Director

- Distinguished academic, clinical scientist and health services leader, having made significant contributions in immunology, diagnostics and health services.
- Previously Pro Vice Chancellor (Health) at Griffith University.
- Currently Professor Emeritus at Griffith University, leading the Mucosal Immunology Research Group (MIRG) and NED of Neurotech International Ltd.

Management with biotech track record

DR LEEARNE HINCH

Chief Executive Officer

- Dr Leearne Hinch BSc BVMS MBA is an experienced biotechnology executive and life sciences commercialisation consultant.
- Strong track record in company leadership, business strategy, operational management, fundraising, sales, business development and technology commercialisation.
- Previous senior executive and consulting roles in ASX-listed biotechnology, multi-national and private companies across diagnostics, devices, therapeutics and animal health.

DR PETER FRENCH PhD

Chief Scientific Officer

- Dr Peter French BSc MSc PhD MBA is a biotechnology executive and respected scientist with extensive CSO, CEO and director experience.
- Successful track record in commercialising medical innovations with over 40 years' scientific expertise in cell and molecular biology, and over 40 peer reviewed publications across oncology, oncology, immunology, microbiology and neuroscience.
- Previous leadership roles in academia and industry across diagnostics and therapeutics.

DR WAYNE JENSEN PhD

R&D Director

- Dr Wayne Jensen PhD is an experienced medtech executive with extensive product development experience.
- Strong track record in product development from concept to commercialisation, having successfully brought 25 products to market including IVDs.
- Previous senior R&D, QA and consulting roles in medtech and diagnostics.

DR EMILY STEIN PhD

R&D Manager (USA)

- Dr Emily Stein PhD is an experienced life sciences executive and scientist, and is inventor of the NET technology.
- Strong track record in creating patented technologies and translating innovations from idea to commercialised products, with expertise in microbiology, rheumatology immunology and neurology.
- Previous leadership roles as founder and scientist in US-based life science start-ups.

TONY DI PIETRO

CFO & Company Secretary

- Tony Di Pietro BComm CA AGIA MAICD is a Chartered Accountant with strong corporate accounting experience, gained in Australia and the UK.
- Graduate Diploma of Applied Corporate Governance from the Governance Institute of Australia and member of the Australian Institute of Company Directors.
- Previous senior roles in ASX-listed biotechnology companies including Acrux Ltd.

Strong patent portfolio

- Broad patent portfolio covering BD1's core technologies and products
- Exclusive IP ownership / licensing
- 25 granted patents, 34 pending and 2 new provisional patent applications
- Covers key jurisdictions (including US, Europe, Asia & Australia)

Patent Family	Title	Granted	Pending	Expiry
SubB2M				
PCT/AU2017/051230 (WO 2018/085888)	Subtilase cytotoxin B subunit mutant		AU, BR, CA, CN, EP, IN, JP, KR, US	2037
APPA/2021901444	Methods of analysing a sample			2042
BARD1				
PCT/FR01/02731 (WO/2002/018536)	Truncated BARD1 protein, and its diagnostic and therapeutic uses	JP, US		JP 2021 US 2024
PCT/IB2011/053635 (WO/2012/023112)	BARD1 isoforms in lung and colorectal cancer and use thereof	AU, CA, CN, EP, HK, IL, JP, US	BR, SG, US (divisional)	2031
PCT/IB2011/054194 (WO/2012/038932)	Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof	EP, US	US (divisional)	2031
PCT/EP2014/073834 (WO/2015/067666)	Lung Cancer Diagnosis	IL	AU, CA, CN, EP, HK, JP, KR, SG, US	2034
EP14002398.7	Non-coding RNA as diagnostic marker and treatment target	US	US (continuation)	2035
hTERT				
PCT/AU2015/050060 (WO2015/120523)	Method of resolving inconclusive cytology to detect cancer	AU, CN, EP, JP, US	IL, US	2035
PCT/AU2016/050764 (WO2017/027928)	Method of detecting cancer in morphologically normal cells		AU, CN, EP, IL, JP, US	2036
Molecular NETs				
PCT/US2010/058086 (WO2011/066449)	Devices for detection of analytes	CN, US, US (cont)	IN	2030
PCT/US2013/049779 (WO2014/011673)	Molecular Nets	EP		2033
PCT/US2014/029823 (WO2014/153262)	Molecular nets on solid phases	AU, CN	CA, CN	2034
APPA/2021901358	Methods relating to tumour-derived extracellular vesicles			2042